Загрузка...
Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells
Hepatocellular carcinoma (HCC) is a common and deadly cancer worldwide and is often refractory to chemotherapy due to the development of multidrug resistance. Lonafarnib is an orally active and potent non-peptidomimetic inhibitor of farnesyl transferase. Here, using in vitro HCC cell models, we demo...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5739619/ https://ncbi.nlm.nih.gov/pubmed/29285232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22086 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|